More News! Sanofi’s HIV Treatment, German Biotech takes on Flu

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

  • Atriva received €3M as a milestone from its investors for a preclinical development step towards an antiviral flu treatment.
  • Alcon handed global rights to Jetrea, a retinal disorder treatment, back to Thrombogenics, whose stock jumped 15% following the announcement on Monday morning.
  • Synpromics, our Scottish former biotech of the week, has joined Solid Biosciences in a gene therapy research partnership to develop new Duchenne muscular dystrophy treatments

  • Pharnext changed its Phase III pivotal trial protocol for PXT3003 in Charcot-Marie-Tooth Disease, but there were no safety issues, and milestones have not been changed.
  • Trefyma, licensed by Morphosys to Janssen, will start two new Phase III studies in Psoriatic Arthritis
  • Sanofi is manufacturing a trispecific antibody as an HIV treatment for the NIH: the French pharma just reported that it protected monkeys against the simian equivalent of the disease and performed better than three individual antibodies.
  • VarmX, a biotech drawing inspiration from snake venom to restore blood clotting, announced the publication of preclinical results in Nature Communications
  • The Canadian-European Trade Agreement (CETA) has taken effect. Leaders hope it will save everyone taxes and make business smoother.
  • Lysogene held its first Parent Advisory Board for a rare childhood disease to better understand its patients’ needs.
  • OncoQR ML has announced its vaccine platform can activate immunological pathways through broad checkpoint control

Images via Parkol, Tilo G, Nacho Such /

Let's Continue The Conversation

Feel free to send us comments about this article to [email protected] and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.